Introduction {#S1}
============

*Pseudomonas aeruginosa* causes acute and chronic infections in immunocompromised patients ([@B3]). Emergence of drug-resistant *P. aeruginosa* strains greatly increases the difficulty of clinical treatment. Fluoroquinolone antibiotics have been used to treat *P. aeruginosa* infections ([@B2]; [@B29]). *P. aeruginosa* encodes multiple resistant determinants against fluoroquinolone antibiotics, such as multidrug efflux systems and pyocyanin ([@B39]; [@B19]). However, chromosomally encoded pyocin biosynthesis genes increase the bacterial susceptibility to fluoroquinolone antibiotics ([@B7]; [@B40]; [@B13]). Ninety percent of *P. aeruginosa* strains produce pyocins, and each *P. aeruginosa* strain usually produces multiple types of the pyocins ([@B32]; [@B22]). Expression of the pyocin biosynthesis genes is activated by PrtN, while a λ CI homologous protein PrtR directly represses the transcription of *prtN* ([@B31]). Genotoxic agents, including fluoroquinolone antibiotics and mitomycin-C, cause DNA damages, leading to the activation of RecA and subsequent SOS response. The activated RecA induces cleavage of PrtR, resulting in derepression of PrtN and production and release of pyocins, which are accompanied by lysis of the producer cells ([@B36]).

Polynucleotide phosphorylase (PNPase) is a highly conserved exonuclease that degrades both RNA and ssDNA. In the presence of Mg^2+^ and inorganic phosphate (Pi), PNPase displays a 3′--5′ exoribonuclease activity. Meanwhile, PNPase can polymerize rNDP into RNA independent of a template. Thus, PNPase plays an important role in RNA metabolism in both prokaryotic and eukaryotic organisms ([@B10], [@B11]; [@B9]). In addition, in the presence of either Fe^3+^ or Mn^2+^ PNPase can polymerize dNDPs into ssDNA without a template. It also possesses a 3′--5′ exodeoxyribonuclease activity ([@B17]; [@B23]; [@B5]). PNPase contains two PH domains at the N-terminus, forming a catalytic core and C-terminal RNA binding KH and S1 domains ([@B6]; [@B8]; [@B20]). In addition, PNPase interacts with ribonuclease E, RNA helicase RhlB and enolase in certain species of Gram-negative bacteria, forming a RNA degradosome that plays an important role in mRNA decay ([@B12]; [@B34]). PNPase has been shown to be involved in bacterial responses to environmental stresses ([@B30]; [@B9]). In *Yersinia* and *Campylobacter jejuni*, PNPase is crucial for the growth at low temperatures ([@B24]; [@B26]). In *Escherichia coli* and *Bacillus subtilis*, PNPase protects the bacterium against oxidative stresses mainly by promoting repair of oxidatively damaged DNA ([@B25]; [@B10], [@B11]; [@B44]) and contributes to bacterial survival upon UV radiation ([@B10], [@B11]; [@B37]). PNPase has also been shown to be involved in the virulence of bacterial pathogens, including *Yersinia*, *Salmonellae*, and *Helicobacter pylori* ([@B38]; [@B28]; [@B15]; [@B18]).

Previously, we demonstrated that PNPase is an essential gene in *P. aeruginosa*. Deletion of the KH and S1 domains results in downregulation of the type III secretion system and upregulation of the type VI secretion system ([@B15]). However, the role of PNPase in *P. aeruginosa* response to environmental stresses, such as antibiotics remains unknown. Here in this study, we found that mutation of the *pnp* increases the bacterial tolerance to fluoroquinolone antibiotics due to downregulation of the pyocin biosynthesis genes. We further demonstrated that the 5′-untranslated region (5′-UTR) of the *prtR* mRNA is involved in the PNPase mediated translational repression. Therefore, our results revealed a novel regulatory mechanism of pyocin production and the related bacterial resistance against ciprofloxacin.

Materials and Methods {#S2}
=====================

Bacterial Strains, Growth Conditions, Plasmids and Primers {#S2.SS1}
----------------------------------------------------------

The bacterial strains, plasmids and primers used in this study were listed in [Table 1](#T1){ref-type="table"} ([@B21]; [@B27]; [@B16]; [@B40]; [@B15], [@B13]). All bacterial strains were cultured in Luria--Bertani (LB) broth (5 g/L Nacl, 5 g/L yeast extract and 10 g/L tryptone, pH 7.4) at 37^∘^C with agitation at 200 rpm. All chromosomal gene mutations were generated as described previously ([@B27]).

###### 

Bacterial strains, plasmids and primers used in this study.

  **Strain/Plasmid/Primer**                     **Description**                                                                                              **Source/Purpose**
  --------------------------------------------- ------------------------------------------------------------------------------------------------------------ ------------------------
  ***P. aeruginosa***                                                                                                                                        
  PAK                                           Wild type strain of *Pseudomonas aeruginosa*                                                                 David Bradley
  Δ*KH-S1*                                      PAK with *pnp* (KH and S1) deletion                                                                          [@B15]
  Δ*KH-S1* /Tn7T-*pnp*                          PAKΔ*KH-S1* with *pnp* inserted on chromosome with mini-Tn7T insertion;                                      [@B15]
  PAKΔPA0614                                    PAK deleted of PA0614                                                                                        This study
  PAKΔPA0629                                    PAK deleted of PA0629                                                                                        This study
  PAKΔ*prtN*                                    PAK deleted of *prtN*                                                                                        This study
  Δ*KH-S1*ΔPA0614                               PAKΔ*KH-S1* deleted of PA0614                                                                                This study
  Δ*KH-S1*ΔPA0629                               PAKΔ*KH-S1* deleted of PA0629                                                                                This study
  Δ*KH-S1*Δ*prtN*                               PAKΔ*KH-S1* deleted of *prtN*                                                                                This study
  PAK/pMMB67EH                                  PAK containing plasmid pMMB67EH                                                                              This study
  Δ*KH-S1*/pMMB67EH                             PAKΔ*KH-S1* containing plasmid pMMB67EH                                                                      This study
  PAK/pMMB67EH-*prtR*                           PAK containing plasmid pMMB67EH-*prtR*                                                                       [@B13]
  **Plasmid**                                                                                                                                                
  pEX18Tc                                       Gene replacement vector; Tc^r^, *oriT*^+^, *sacB*^+^                                                         [@B27]
  pUC18T-mini-Tn7T-Tc                           mini-Tn7 base vector from insertion into chromosome attTn7 site; Tc^r^                                       [@B16]
  pUC18T-mini-Tn7T-P*prtR*-lacZ                 *prtR* promoter of PAK fused to promoterless *lacZ* on pUC18T-mini-Tn7T                                      [@B40]
  pMMB67EH                                      Expression vector with tac promoter;Ap^r^                                                                    [@B21]
  pUCP20 (no promoter)                          *Escherichia-Pseudomonas* shuttle vector; no promoter; Amp^r^                                                This study
  pUCP20(no promoter) -pRkaraRed(43)-PrtR-His   6 × His-tagged PrtR driven by the P~BAD~ promoter with 43 bp of the 5′-UTR sequence on pUCP20(no promoter)   This study
  pUCP20(no promoter) -pRkaraRed(15)-PrtR-His   6 × His-tagged PrtR driven by the P~BAD~ promoter with 15 bp of the 5′-UTR sequence on pUCP20(no promoter)   This study
  pUCP20(no promoter) -pRkaraRed(43)-GFP        GFP driven by the P~BAD~ promoter with 43 bp of the 5′-UTR sequence on pUCP20(no promoter)                   This study
  pUCP20(no promoter) -pRkaraRed(15)-GFP        GFP driven by the P~BAD~ promoter with 15 bp of the 5′-UTR sequence on pUCP20(no promoter)                   This study
  **Primer**                                    **Sequence (5′→3′)**                                                                                         **Function**
  PA0636-RT-S                                   TGGAAGACCCGGCAGAAG                                                                                           RT-PCR
  PA0636-RT-AS                                  CGTTGAGCTTGGACAGATCCT                                                                                        RT-PCR
  PA0614-RT-S                                   CGCTGCCTGCCAAGGA                                                                                             RT-PCR
  PA0614-RT-AS                                  ATCAGTACCCAGAGCGGCATT                                                                                        RT-PCR
  PA0629-RT-S                                   GTGGAGAACCTCAATTACAG                                                                                         RT-PCR
  PA0629-RT-AS                                  TAGGTGTTGTCGGCAATC                                                                                           RT-PCR
  *prtR*-RT-S                                   GATGCGCAACCTGAAGCA                                                                                           RT-PCR
  *prtR*-RT-AS                                  TGAATGGTGTTCTGCGAAACC                                                                                        RT-PCR
  *prtN*-RT-S                                   CGACGATAGCCACAAG                                                                                             RT-PCR
  *prtN*-RT-AS                                  GGATGCGATGCTGTC                                                                                              RT-PCR
  *lexA*-RT-S                                   AATCCCGCCTTCTTCAAT                                                                                           RT-PCR
  *lexA*-RT-AS                                  AATGCCGATGTCCTTCAT                                                                                           RT-PCR
  *recA*-RT-S                                   ATATCAAGAACGCCAACT                                                                                           RT-PCR
  *recA*-RT-AS                                  TAGAACTTCAGTGCGTTA                                                                                           RT-PCR
  BamHI-P*prtR*-*lacZ*-S^\#^                    CGC[GGATCC]{.ul} GAGCCAGGACCAGTTCGTTGGC                                                                      Transcriptional fusion
  HindIII-*lacZ*-AS                             ATTATA[AAGCTT]{.ul} TTATTTTTGACACCAGACCAACTGG                                                                Transcriptional fusion
  SacI-P~BAD~-S                                 CCAA[GAGCTC]{.ul} TTATGACAACTTGACGGC                                                                         Translational fusion
  HindIII-*prtR*-AS                             ATTATA[AAGCTT]{.ul} TCAGTGGTGGTGGTGGTGGTGACCTCCCC GCACCAGGGACGGGCCGC                                         Translational fusion
  XhoI- *prtR*(43)-GFP S                        CCG[CTCGAG]{.ul} TAGGCTCTTTACAGAAAATCCATCGGTCTGTAGA TTGCCGAGCATGAGTAAAGGAGAAGAACTTTTCACTG                    Translational fusion
  XhoI- *prtR*(15)-GFP S                        CCG[CTCGAG]{.ul} TGTAGATTGCCGAGCATGAGTAAAGGAGAAGAA CTTTTCACTG                                                Translational fusion
  HindIII --GFP-AS                              CCC[AAGCTT]{.ul} TTATTTGTATAGTTCATCCATGCCATG                                                                 Translational fusion

\#

The endonuclease cutting sites are underlined.

Minimum Inhibitory Concentration and Survival Assay {#S2.SS2}
---------------------------------------------------

Minimum inhibitory concentrations were determined by the twofold serial dilution method as described previously ([@B19]). Overnight bacterial cultures were diluted 1:50--1:100 in LB and cultured at 37^∘^C until the OD~600~ reached 0.8--1.0. The bacterial concentration was adjusted to 1 × 10^5^ CFU/ml and 200 μl of the bacteria was added to each well of a 96-well plate (Corning). The plate was incubated for 24 h at 37^∘^C without agitation. The Minimum inhibitory concentration was recorded as the lowest concentration of antibiotic that inhibited visible growth. For the survival assay, bacteria were grown to an OD~600~ of 1.0 at 37^∘^C. Then the bacteria were treated with ciprofloxacin at indicated concentrations at 37^∘^C with agitation at 200 rpm. The numbers of live cells before and after antibiotic treatment were determined by serial dilution and plating assay.

RNA Extraction, Reverse Transcription, and Quantitative RT-PCR {#S2.SS3}
--------------------------------------------------------------

Overnight bacterial cultures were diluted 1:50--1:100 into fresh LB with and without 0.016 μg/ml ciprofloxacin and grown to an OD~600~ of 0.8--1.0. Total RNA was isolated with an RNeasy Mini kit (Tiangen Biotech, Beijing, China) and cDNA was synthesized with a PrimeScript Reverse Transcriptase (TaKaRa, Dalian, China). 1 μg RNA was used for reverse transcription. In the quantitative RT-PCR experiment, the cDNA was mixed with specific forward and reverse primers and the SYBR Premix Ex Taq^TM^ II (TaKaRa). The CFX Connect Real-Time system (Bio-Rad, United States) was used to perform the quantitative RT-PCR. *rpsL*, which encodes the 30S ribosomal protein S12 was used as an internal control.

Western Blotting {#S2.SS4}
----------------

Samples from the same number of bacterial cells were loaded onto 10 or 12% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gel. Then the proteins were transferred onto a polyvinylidene difluoride (PVDF) membrane and probed with a GFP antibody or a mouse monoclonal antibody against the 6 × His tag (1:2000; Cell Signaling Technology, United States) at room temperature for 1--2 h or overnight at 4^∘^C. Then the PVDF membrane was washed with 1 × phosphate-buffered saline (1 × PBS, 5.4 mM KCl, 20 mM Na~2~HPO~4~, 274 mM NaCl, 4 mM KH~2~PO~4~, pH 7.4) containing 2% 24 times. Next, the PVDF membrane was incubated with an anti-rabbit IgG (1: 2,000; Promega, United States) at room temperature for 1.5 h. Signals were detected by an ECL Plus kit (Millipore). The signals were visualized by a Bio-Rad molecular imager (ChemiDocXRS). The RNA polymerase α subunit RpoA was used as a loading control (with an antibody from Biolegend).

Promoter Activity Assay {#S2.SS5}
-----------------------

The promoter region of the *prtR* gene was amplified by PCR with the primers shown in [Table 1](#T1){ref-type="table"}. The PCR product was fused with the coding sequence of *lacZ*. The P*~prtR~*-*lacZ* fusion was inserted into the chromosome of *P. aeruginosa* strains via a miniTn7 vector ([@B16]). To measure the expression level of LacZ, the bacteria were grown to an OD~600~ of 0.5, and then treated with ciprofloxacin at indicated concentrations for 3 h. The β-galactosidase activities were measured as described previously ([@B43]). Briefly, each sample (0.5 ml bacteria) was collected by centrifugation and resuspended in 1.5 ml Z buffer (60 mM NaH~2~PO~4~, 60 mM Na~2~HPO~4~, 1 mM MgSO~4~, 10 mM KCl and 50 mM β-mercaptoethanol, pH 7.0). 0.5 ml of the suspension was mixed with 10 μl 0.1% SDS (BBI Life Sciences, Shanghai, China) and 10 μl chloroform (BBI Life Sciences, Shanghai, China), and then vortexed for 10--15 s. The remaining 1 ml was used for OD~600~ measurement. 100 μl ONPG (40 mg/ml; Sigma, United States) was added to each sample, followed by incubation at 37^∘^C. When the color turned into light yellow, 0.5 ml 1 M Na~2~CO~3~ was added to the mixture to stop the reaction. OD~420~ was measured, and the time was recorded. The β-galactosidase activity (Miller units) was calculated as (1000 × OD~420~)/(T × V × OD~600~). T, reaction time (minute); V, bacteria volume (ml).

Results {#S3}
=======

PNPase Influences the Bacterial Resistance to Ciprofloxacin {#S3.SS1}
-----------------------------------------------------------

To test the role of PNPase in antibiotic resistance of *P. aeruginosa*, we determined the MICs of various antibiotics against wild type PAK and an isogenic mutant with the deletion of the KH-S1 domains of PNPase (Δ*KH-S1*) ([Figure 1A](#F1){ref-type="fig"}; [@B15]). The two strains displayed similar levels of resistance (MICs) to most of the tested antibiotics, including erythromycin, carbenicillin and gentamicin. However, the MICs of ciprofloxacin and ofloxacin were increased four and two fold in the Δ*KH-S1* mutant, respectively ([Table 2](#T2){ref-type="table"}). Complementation with a *pnp* gene restored the bacterial susceptibility ([Table 2](#T2){ref-type="table"}). Consistent with the MIC test results, in the presence of 0.16 μg/ml (1 × MIC) ciprofloxacin, deletion of the KH-S1 domains increased the bacterial survival rate by approximately 100-fold, which was restored by complementation with a *pnp* gene ([Figure 1B](#F1){ref-type="fig"}).

![Bacterial survival rates under the treatment of ciprofloxacin. **(A)** Domains of the PNPase of *Pseudomonas aeruginosa*. **(B)** PAK, Δ*KH-S1* mutant and the complemented strain (Δ*KH-S1*/Tn7T-*pnp*) were grown to an OD~600~ of 1.0 at 37^∘^C and treated with 0.16 μg/ml ciprofloxacin for 6 h. At indicated time points, the bacterial survival rates were determined by serial dilution and plating assay. ^∗∗∗^*p* \< 0.001 by Student's *t*-test.](fmicb-10-01762-g001){#F1}

###### 

Bacterial susceptibilities to antibiotics.

                        **MIC (μg/ml)**                     
  --------------------- ----------------- ----- ----- ----- -------
  PAK                   0.16              1.5   150   125   0.625
  Δ*KH-S1*              0.64              3     150   125   0.625
  Δ*KH-S1*/Tn7T-*pnp*   0.16              1.5   150   125   --

"--" Indicates that the complemented strain is resistant to gentamicin due to the miniTn7T insertion.

Downregulation of Pyocin Biosynthesis Genes Contributes to the Increased Resistance to Ciprofloxacin in the ΔKH-S1 Mutant {#S3.SS2}
-------------------------------------------------------------------------------------------------------------------------

In our previous transcriptome analysis of the Δ*KH-S1* mutant, no alternation was observed on the expression of the multidrug efflux system genes, whereas the pyocin biosynthesis genes were downregulated ([@B15]). Due to the role of pyocins in the bacterial susceptibility to ciprofloxacin ([@B7]; [@B40]; [@B13]), we verified the expression levels of the R-type (*PA0614*) and F-type pyocins (*PA0629*, *PA0633*, and *PA0636*) genes by real time PCR ([@B33]; [@B32]). Due to the difference in the MICs of ciprofloxacin to wild type PAK and the Δ*KH-S1* mutant, we treated both strains with 0.016 μg/ml ciprofloxacin (1/10 MIC to PAK), which did not affect the growth of both strains. In the presence or absence of ciprofloxacin, the mRNA levels of the pyocin biosynthesis genes were lower in the Δ*KH-S1* mutant than those in wild type PAK. Complementation with a *pnp* gene restored the mRNA levels in the Δ*KH-S1* mutant ([Figure 2](#F2){ref-type="fig"}). In PAK, the resistance to ciprofloxacin was increased upon deletion of *prtN*, *PA0614*, and *PA0629*, which encode the transcriptional activator for the pyocin biosynthesis genes, a holin- and a lysozyme-like protein, respectively ([Table 3](#T3){ref-type="table"}). However, deletion of those genes in the Δ*KH-S1* mutant did not further increase the resistant level ([Table 3](#T3){ref-type="table"}), indicating that the repression of pyocin biosynthesis genes might result in the increased resistance to ciprofloxacin.

![Expression levels of pyocin biosynthesis genes in the ΔKH-S1 mutant. PAK, Δ*KH-S1* and the complemented strain were grown to an OD~600~ of 0.8--1.0 at 37^∘^C with or without 0.016 μg/ml ciprofloxacin, followed by RNA extraction. The mRNA levels of *prtN*, *PA0614*, *PA0629*, *PA0633*, and *PA0636* were determined by real-time PCR with *rpsL* as the internal control. ^∗∗∗^*p* \< 0.001 by Student's *t*-test.](fmicb-10-01762-g002){#F2}

###### 

Bacterial susceptibilities to ciprofloxacin.

  **Strain**                **MIC (μg/ml)**
  ------------------------- -----------------
  PAK                       0.16
  ΔPA0614                   0.32
  ΔPA0629                   0.32
  Δ*prtN*                   0.32
  Δ*KH-S1*                  0.64
  Δ*KH-S1*ΔPA0614           0.64
  Δ*KH-S1*ΔPA0629           0.64
  Δ*KH-S1*Δ*prtN*           0.64
  PAK/pMMB67EH              0.16
  PAK/pMMB67EH-*prtR*-His   0.64
  Δ*KH-S1*/pMMB67EH         0.64

The PrtR Protein Level Is Increased in the ΔKH-S1 Mutant {#S3.SS3}
--------------------------------------------------------

PrtR directly represses the transcription of *prtN* that encodes the transcriptional activator of the pyocin biosynthesis genes ([@B31]). Since the mRNA level of *prtN* was lower in the Δ*KH-S1* mutant ([Figure 2](#F2){ref-type="fig"}), we suspected that the PrtR protein level might be higher in the Δ*KH-S1* mutant. To test the protein level of PrtR, we utilized a C-terminal 6 × His-tagged *prtR* driven by its native promoter (designated as P*~prtR~*-*prtR*-His) ([Figure 3A](#F3){ref-type="fig"}; [@B40]). Indeed, the PrtR-His level was higher in the Δ*KH-S1* mutant than that in PAK in the presence or absence of ciprofloxacin ([Figure 3B](#F3){ref-type="fig"}). In addition, overexpression of *prtR* in PAK increased the MIC of ciprofloxacin by fourfold and enhanced the survival rate in the presence of ciprofloxacin to the similar level as that of the Δ*KH-S1* mutant ([Figure 3C](#F3){ref-type="fig"} and [Table 3](#T3){ref-type="table"}). These results suggest that the increased resistance to ciprofloxacin is likely due to the higher protein level of PrtR in the Δ*KH-S1* mutant.

![Expression of PrtR in the ΔKH-S1 mutant. **(A)** Fragments of the prtR promoter region fused with the prtR-His or a promoterless lacZ gene. **(B)** Protein levels of PrtR-His in PAK and the Δ*KH-S1* mutant carrying the P*~prtR~*-*prtR*-His on the bacterial chromosome. The bacterial cells were grown to an OD~600~ of 1.0, and then incubated with or without 0.06 μg/ml ciprofloxacin for 1 h. The PrtR-His levels were determined by Western blotting. RpoA was used as the loading control. **(C)** PAK containing an empty vector or the *prtR* overexpression plasmid was grown to an OD~600~ of 1.0 and treated with 0.16 μg/ml ciprofloxacin for 6 h. At indicated time points, the bacterial survival rate was determined by serial dilution and plating. ^∗∗∗^*p* \< 0.001 by Student's *t*-test.](fmicb-10-01762-g003){#F3}

PNPase Affects the Expression of PrtR at the Post-transcription Level Through Its 5*′*-UTR {#S3.SS4}
------------------------------------------------------------------------------------------

To understand the mechanism of the increased PrtR level, we examined the promoter activity by utilizing a transcriptional fusion of *lacZ* reporter gene with the promoter of *prtR* (P*~prtR~*-*lacZ*). The presence of ciprofloxacin induced the *lacZ* expression in wild type PAK, however, the *lacZ* expression levels in the Δ*KH-S1* mutant were lower than those in PAK in the presence of the same concentrations of ciprofloxacin ([Figure 4A](#F4){ref-type="fig"}). Consistent with the above results, the mRNA level of *prtR* was lower in the Δ*KH-S1* mutant ([Figure 4B](#F4){ref-type="fig"}), which might be due to an auto-repression of PrtR ([@B40]). Nevertheless, this result indicates that the upregulation of PrtR in the Δ*KH-S1* mutant might be mediated through a post-transcriptional mechanism.

![The promoter activity and mRNA level of prtR in the ΔKH-S1 mutant. **(A)** Expression of P*~prtR~*-*lacZ* in PAK and the Δ*KH-S1* mutant. The bacteria were grown to an OD~600~ of 0.5, and then treated with ciprofloxacin at indicated concentrations for 3 h, followed by the β--galactosidase assay. ^∗∗∗^*p* \< 0.001 by Student's *t*-test. **(B)** PAK, Δ*KH-S1* and the complemented strain were grown to an OD~600~ of 0.8--1.0 at 37^∘^C with or without 0.016 μg/ml ciprofloxacin. The mRNA levels of *prtR* were determined by real-time PCR with *rpsL* as the internal control. ^∗∗∗^*p* \< 0.001 by Student's *t*-test.](fmicb-10-01762-g004){#F4}

Previous studies demonstrated that the stability of PrtR is regulated by RecA in response to genotoxic agents ([@B40]). Treatment with ciprofloxacin induced similar expression levels of *recA* and *lexA* in the Δ*KH-S1* mutant and PAK, indicating a similar level of SOS response ([Figure 5A](#F5){ref-type="fig"}). To examine the PrtR protein stability, we constructed a C-terminal 6 × His-tagged PrtR driven by an inducible P~BAD~ promoter with an exogenous ribosome binding site from the vector pET28a, resulting in P~BAD~-SD-*prtR*-His ([Figure 5B](#F5){ref-type="fig"}). In the absence of ciprofloxacin, the levels of the PrtR-His were similar in the Δ*KH-S1* mutant and PAK. Treatment with ciprofloxacin resulted in a similar degradation rate of the PrtR-His in both strains ([Figures 5C,D](#F5){ref-type="fig"}).

![PrtR protein stabilities in PAK and the ΔKH-S1 mutant. **(A)** PAK, ΔKH-S1 and the complemented strain were grown to an OD600 of 0.8--1.0 at 37^∘^C with or without 0.016 μg/ml ciprofloxacin. The mRNA levels of *lexA* and *recA* were determined by real-time PCR with *rpsL* as the internal control. ns, not significant by Student's *t*-test. **(B)** The C-terminal 6 × His-tagged *prtR* is driven by an inducible P~BAD~ promoter with an exogenous ribosome binding site (designated as P~BAD~-SD-*prtR*-His). The ribosome binding sequence was underlined. **(C,D)** Strains carrying the P~BAD~-SD-*prtR*-His were grown to an OD~600~ of 0.6--0.8 at 37^∘^C, followed by induction with 0.2% arabinose for 1.5 h. Then, 500 μg/ml chloramphenicol and 0.016 μg/ml ciprofloxacin were added to the medium. At the indicated time points, bacterial cells of each strain were collected and the levels of PrtR-His were determined by Western blotting. RpoA was used as the loading control. The relative intensity of each band was quantified by ImageJ.](fmicb-10-01762-g005){#F5}

We then examined whether the translation of the *prtR* mRNA is affected in the Δ*KH-S1* mutant. Since the 5′ untranslated region (5′-UTR) of a mRNA is usually involved in the translational regulation, we constructed a 6 × His-tagged *prtR* driven by an exogenous P~BAD~ promoter with 43 bp of the *prtR* 5′-UTR sequence ([Figure 6A](#F6){ref-type="fig"}). The translation of the PrtR was higher in the Δ*KH-S1* mutant ([Figure 6B](#F6){ref-type="fig"}). To identify the region involved in the post-transcriptional regulation, we reduced the 5′-UTR sequence to 15 bp, resulting in P~BAD~-15-*prtR*-His ([Figure 6A](#F6){ref-type="fig"}). From this construct, similar levels of PrtR-His were observed in the Δ*KH-S1* mutant and wild type PAK ([Figure 6C](#F6){ref-type="fig"}). As the coding region might be involved in the translational regulation, we replaced the *prtR* coding sequence with a *gfp* gene, resulted in P~BAD~-43-*gfp* and P~BAD~-15-*gfp*, respectively ([Figure 6A](#F6){ref-type="fig"}). Fusion with the 43 bp 5′-UTR of *prtR* resulted in higher GFP level in the Δ*KH-S1* mutant, which was restored by complementation with a *pnp* gene ([Figure 6D](#F6){ref-type="fig"}). However, reduction of the 5′-UTR to 15 bp resulted in similar levels of GFP ([Figure 6E](#F6){ref-type="fig"}). These results suggest that the 5′-UTR of the *prtR* mRNA might be involved in the PNPase mediated post-transcriptional regulation of PrtR.

![Translational regulation of prtR by the PNPase. **(A)** Structures of the 6 × His-tagged *prtR* fusions. P~BAD~-43-*prtR*-His and P~BAD~-15-*prtR*-His represent 6 × His-tagged *prtR* driven by the P~BAD~ promoter with 43 and 15 bp of the 5′-UTR sequence of the *prtR* gene, respectively. The *prtR* open reading frame was replaced by a *gfp* gene, resulting in P~BAD~-43-*gfp* and P~BAD~-15-*gfp*. The potential ribosome binding site (RBS) was shown in bold underlined letters. Strains containing the *prtR*-His or *gfp* expression plasmid were grown to an OD~600~ of 1.0 and then induced with 0.2% arabinose for 1.5 h. Protein levels of PrtR **(B,C)** and GFP **(D,E)** were determined by Western blotting. RpoA was used as the loading control.](fmicb-10-01762-g006){#F6}

Discussion {#S4}
==========

In this study, we found that deletion of the KH-S1 domains of the PNPase increased the bacterial resistance to fluoroquinolone antibiotics. We further demonstrated that the PrtR level is increased in the Δ*KH-S1* mutant, which reduces the PrtN expression, resulting in downregulation of the pyocin biosynthesis genes in the presence of ciprofloxacin.

The PNPase is a conserved exoribonuclease that degrades single stranded RNA. It contains two N-terminal PH domains that possess the ribonuclease activity, and C-terminal KH and S1 domains that are involved in the binding of RNAs. The PNPase plays an important role in the maturation of rRNAs and tRNAs. Besides, the PNPase has been shown to control gene expression through sRNAs. In *Salmonella typhimurium*, Hfq independent sRNAs CsrB, CsrC, and CopA are initially cleaved by RNase E, followed by degradation by PNPase ([@B42]). In *E. coli*, PNPase degrades the sRNAs SgrS, GlmY, MicA, and RyhB when they are not bond to Hfq ([@B1]). Meanwhile, PNPase also increases the stability of certain Hfq-bond sRNAs ([@B4]). For instance, deletion of *pnp* in *E. coli* resulted in reduced level of ArcZ, a negative regulator of *mutS*. Consequently, upregulation of *mutS* in the *pnp* mutant decreases bacterial spontaneous mutation rate ([@B14]).

Previously, we demonstrated that PNPase regulates type VI secretion system through degradation of the sRNAs RsmY and RsmZ ([@B15]). In this study, we found that a 43-nucleotide 5′-UTR of the *prtR* mRNA is required for the PNPase mediated translational repression. Reduction of the 5′-UTR to 15-nucleotide resulted in the similar levels of the PrtR protein in the Δ*KH-S1* mutant and wild type strain. The 5′-UTR might control gene expression through several mechanisms. For example, formation of a hairpin structure might block the ribosome binding site. PNPase might affect the secondary structure by recruiting an endonuclease. Another possibility is that a sRNA might anneal to the 5′-UTR, which alters the secondary structure or directly blocks the ribosome binding site. In addition, PNPase might directly bind to an mRNA though its KH-S1 domains, which affects the translation. To examine whether PNPase can directly bind to the 5′-UTR of the *prtR* mRNA, we performed an RNA electrophoretic mobility shift assay. However, no interaction was observed (data not show). It might be possible that another protein is required to facilitate the interaction. Further studies are needed to elucidate the regulatory mechanism.

Pyocins are chromosomally encoded bacteriocins produced by most of *P. aeruginosa* strains. Production and release of pyocins under environmental stresses such as the presence of genotoxic agents might provide an advantage in the competition against other bacteria ([@B32]). A recent study revealed that R-type pyocins play an important role in the competition among various *P. aeruginosa* strains during the infection of cystic fibrosis patients ([@B35]). In addition, when pyocins are released through cell lysis, the liberated chromosomal DNA and other components function as the matrix for biofilm formation ([@B41]). However, for the individual pyocins producer cells, the release of pyocins leads to cell death. Therefore, the production of pyocins should be under a tight control. Our study here revealed a novel post-transcriptional regulation on the key regulator PrtR. Further studies are needed to elucidate the molecular details of the regulatory mechanism and the signaling pathway.
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